SCHEMBL24258036

SCHEMBL24258036

O=c1ccc(-c2noc(Cc3c(F)cccc3Cl)n2)c[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.41
RAB9A P51151 3/20 0.39
NPC1 O15118 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
LMNA P02545 3/20 0.39
GLA P06280 1/20 0.39
AKR1B1 P15121 2/20 0.38
TP53 P04637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
DGAT1 O75907 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258021 0.77 ERCC1 (0.48) RAB9ANPC1L3MBTL1LMNARXFP1
SCHEMBL24258072 0.76 MAPK1 (0.58) RAB9AL3MBTL1LMNAMAPTKMT2A
SCHEMBL24258084 0.76 S1PR1 (0.58) RAB9ANPC1L3MBTL1MAPTKMT2A
SCHEMBL24258053 0.76 ERCC1 (0.49) RAB9ANPC1L3MBTL1CASP3LMNA
SCHEMBL26006746 0.76 ERCC1 (0.39) RAB9ANPC1L3MBTL1LMNATP53
SCHEMBL24258023 0.75 S1PR1 (0.43) RAB9ANPC1L3MBTL1LMNAMAPT
SCHEMBL24258039 0.72 ERCC1 (0.45) RAB9ANPC1L3MBTL1LMNAKMT2A
SCHEMBL24258048 0.72 TDP1 (0.57) RAB9ANPC1L3MBTL1LMNAKDM4E
SCHEMBL26004655 0.71 NPC1 (0.39) DAORAB9ANPC1L3MBTL1CASP3
SCHEMBL26004727 0.70 MAPT (0.47) RAB9ANPC1L3MBTL1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 DAO 2114/4885RAB9A 1589/4885NPC1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.